Skip to content

Nabumetone

    Brands

    DEA Class; Rx

    Common Brand Names; Relafen

    NSAIDs 

    NSAID of the acetic acid chemical class; requires conversion to active metabolite for anti-inflammatory, analgesic, and antipyretic activity; causes an increased risk of serious gastrointestinal adverse effects; may cause an increased risk of serious cardiovascular events; use lowest effective dose for the shortest possible duration; once daily administration.

    For the acute and chronic treatment of rheumatoid arthritis or osteoarthritis.
    For the treatment of ankylosing spondylitis.

    Absolute: Aspirin allergy, severe renal impairment; perioperative pain in setting of coronary artery bypass graft (CABG) surgery

    Relative: Duodenal/gastric/peptic ulcer, stomatitis, systemic lupus erythematosus, ulcerative colitis, late pregnancy (may cause premature closure of ductus arteriosus)

    >10%

    Diarrhea (14%)

    Dyspepsia (13%)

    Abdominal pain (12%)

    1-10%

    Constipation (3-9%)

    Dizziness (3-9%)

    Edema (3-9%)

    Flatulence (3-9%)

    Headache (3-9%)

    Nausea (3-9%)

    Positive stool guaiac (3-9%)

    Pruritus (3-9%)

    Rash (3-9%)

    Tinnitus (3-9%)

    Dry mouth (1-3%)

    Fatigue (1-3%)

    Gastritis (1-3%)

    Increased sweating (1-3%)

    Insomnia (1-3%)

    Nervousness (1-3%)

    Somnolence (1-3%)

    Stomatitis (1-3%)

    Vomiting (1-3%)

    Use caution in asthma (bronchial), bleeding disorders, cardiac disease, hepatic impairment, hypertension, renal impairment

    Therapy may lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to increased incidence of CV events; patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs; use with caution in patients with hypertension; monitor blood pressure (BP) closely during initiation of treatment and throughout the course of therapy

    May not be sufficiently activated in patients with hepatic dysfunction; use with caution

    Borderline elevations of 1 or more liver function tests may occur in up to15% of patients; laboratory abnormalities may progress, remain unchanged, or may be transient with continuing therapy; notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) reported in approximately 1% of patients in clinical trials with NSAIDs; If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue therapy

    Pregnancy category: C; D if used for prolonged periods or near term (premature closure of ductus arteriosus)

    Lactation: Unknown whether drug is excreted in breast milk; effect on infant unknown; do not give to nursing mothers

    Adults

    2000 mg/day PO.

    Elderly

    2000 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Tablet

    • 500mg
    • 750mg